Abstract
Objectives:
M1 macrophage polarization and phenotype in Inflammatory Bowel Disease (IBD) are common biological responses.
Method:
Herein, IBD mice models were constructed and macrophages were derived.
Results:
It was discovered that microRNA-146b (miR-146b) was downregulated in IBD mice and Lipopolysaccharide (LPS)-induced macrophages. Moreover, the inhibitory role of overexpressed miR-146b in reducing the inflammation level and blocking M1 macrophage polarization was confirmed. Further investigation indicated that Fibrinogen Like 2 (FGL2) acted as the target gene of miR-146b, and FGL2 mediated activation of NLRP3, NF-κB-p65, and p38-MAPK. More importantly, it was validated that miR-146b could ameliorate inflammatory pheno-type and prevent M1 macrophage polarization via inhibiting FGL2 in vitro, and miR-146b overexpression alleviated the intestinal injury of IBD mice in vivo.
Conclusions:
Overall, it is potential to use miR-146b for the amelioration of IBD.
HIGHLIGHTS
-
miR-146b was downregulated in Inflammatory Bowel Disease (IBD) mice and LPS-induced macrophages.
-
Fibrinogen Like 2 (FGL2) was identified as the target gene of miR-146b.
-
miR-146b ameliorated the inflammation and blocked M1 macrophage polarization via inhibiting FGL2.
-
miR-146b ameliorated the symptoms and pathological injury of IBD via inhibiting FGL2.